Stockhead on MSN2d
AdAlta prioritises ‘East to West’ cellular immunotherapy strategy to drive value creationAdAlta (ASX:1AD) is bringing cellular immunotherapy products from Asian to western markets to drive value creation.
FY25 saw AdAlta focus on increasing its corporate muscle, with two new board members and additional advisors engaged. ...
HotCopper.com on MSN2d
'East to West': AdAlta unveils new strategy to find drug candidates, but appears to've ditched AD-214AdAlta (ASX:1AD) has unveiled a new grand plan to take cell therapy candidates from Southeast Asia, firm them up in ...
Index rose 3.20% in January as markets had a strong start to 2025 with the benchmark S&P/ASX 200 rising by 5% to reach a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback